medimaps group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, proudly announces 510(k) clearance from FDA and MDR certification in EU for the latest version of its flagsh...
GENEVA: medimaps group S.A., a global leader in AI-driven bone microarchitecture imaging solutions, proudly announces 510(k) clearance from FDA and MDR certification in EU for the latest version of its flagship Trabecular Bone Score (TBS) software, TBS Osteo. This next generation software is designed to enhance bone microarchitecture evaluation, broaden patient eligibility, and improve connectivity within medical facilities. The company is planning to rollout the next generation of TBS Osteo in its current 90 markets worldwide.
“At Medimaps, we understand the growing pressures faced by radiology departments. With the next generation of TBS Osteo, we’re equipping clinicians with the tools they need to deliver exceptional care efficiently, without compromising clinical standards," said Univ.-Prof. Dr. Didier Hans, CEO and Co-founder of Medimaps.
TBS Osteo remains the only approved medical device software for evaluating bone microarchitecture in clinical settings. Since 2022 it benefits from four Category 1 reimbursement CPT codes in the US.
By converting DXA scan data into precise, actionable reports, TBS Osteo complements bone mineral density measurements and clinical risk factors, providing clinicians with a comprehensive tool for assessing osteoporotic fracture risks in patients. Medimaps has dedicated over 14 years to the ongoing development of TBS Osteo, striving to meet the evolving needs of both patients and clinicians. TBS Osteo next generation introduces significant advancements:
With over 4 million procedures performed annually and endorsements from more than 30 national and international clinical guidelines, TBS Osteo has become a trusted tool in the assessment and monitoring of bone health in patients developing osteoporosis. Its role extends to research and pharmaceutical clinical trials in the field of women’s health, rheumatology, endocrinology, oncology, and sports medicine, addressing bone fragility as a critical health concern in pathologies impacting bone integrity.
About Medimaps
Founded by medical practitioners and clinical researchers, Medimaps combines Swiss innovation with a global presence to lead in bone health management. We provide healthcare professionals worldwide with advanced AI-driven software that enables comprehensive bone microarchitecture assessment.
Our passion for musculoskeletal health is underpinned by scientific knowledge, collaborations with world-class academics, clinicians, industry partners, and direct patient engagement. The science behind our cutting-edge imaging applications and clinical evidence forms the core of our company’s DNA.
Learn more at www.medimaps.ai
Fonte: Business Wire
Alaa Abdul Nabi, Vice President, Sales International at RSA presents the innovations the vendor brings to Cybertech as part of a passwordless vision for…
G11 Media's SecurityOpenLab magazine rewards excellence in cybersecurity: the best vendors based on user votes
Always keeping an European perspective, Austria has developed a thriving AI ecosystem that now can attract talents and companies from other countries
Successfully completing a Proof of Concept implementation in Athens, the two Italian companies prove that QKD can be easily implemented also in pre-existing…
Halcyon, a leading platform designed from day one to defeat ransomware, today announced that CRN®, a brand of The Channel Company, has named Chris Catanzaro,…
For decades, workplace assessments have been reserved for leaders and managers, until now. Today, SurePeople announces free access to Prism, a proprietary…
#assetmanagement--Strong U.S. equity market returns were offset by weakness in the bond market and global stocks in the fourth quarter of 2024, generating…
Cheesecake Labs, a global leader in mobile and web app development, has announced significant milestones in its 2025 expansion strategy, including the…